J. Sullivan

发表

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1994, The Journal of pharmacology and experimental therapeutics.

Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management.

A. Gomtsyan, Jill M. Wetter, J. Sullivan, 2008, Journal of medicinal chemistry.

Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K+ channel Kir6.2 combination expressed in HEK‐293 cells

J. Sullivan, J. Brioni, C. Shieh, 2000, British journal of pharmacology.

2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437): a novel inhibitor of protein kinase C interacting at the regulatory domain.

J. Sullivan, B. Shearer, J. Connor, 1992, Molecular pharmacology.

Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, Y. Martin, S. Arneric, 1996, Journal of medicinal chemistry.

The neurotoxicity of MPTP and the relevance to Parkinson's disease.

J. Sullivan, K. Tipton, J. M. McCrodden, 1990, Pharmacology & toxicology.

Abstracts, Poster Session

A. Zlotta, O. Rampin, J. Sullivan, 1999, European Urology.

Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics.

J. Sullivan, J. Daly, M. Decker, 2000, Natural product reports.

The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control

J. Sullivan, M. Decker, M. Meyer, 2001, Expert opinion on investigational drugs.

(+/-)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors.

D. Donnelly-roberts, J. Sullivan, D. Anderson, 1994, The Journal of pharmacology and experimental therapeutics.

Functional implication of spare ATP-sensitive K(+) channels in bladder smooth muscle cells.

J. Sullivan, J. Brioni, C. Shieh, 2001, The Journal of pharmacology and experimental therapeutics.

A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat

Matthew S. Johnson, J. Sullivan, C. Shieh, 2007, Proceedings of the National Academy of Sciences.

Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia

A. Gomtsyan, P. Mantyh, J. Sullivan, 2009, Pain.

Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H 3 Receptor Antagonist

Min Zhang, K. Browman, Jill M. Wetter, 2005 .

Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?

J. Sullivan, M. Dart, M. Meyer, 2006, British journal of pharmacology.

2,6-Diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)hexanamide (NPC 15437): A selective inhibitor of protein kinase C

J. Sullivan, B. Shearer, J. Connor, 1991, Agents and Actions.

Cloning and transient expression of genes encoding the human α4 and β2 neuronal nicotinic acetylcholine receptor (nAChR) subunits

S. Arneric, J. Sullivan, T. Giordano, 1995 .

Cloning and transient expression of genes encoding the human alpha 4 and beta 2 neuronal nicotinic acetylcholine receptor (nAChR) subunits.

S. Arneric, J. Sullivan, T. Giordano, 1995, Gene.

Novel isoxazoles which interact with brain cholinergic channel receptors have intrinsic cognitive enhancing and anxiolytic activities.

S. Arneric, J. Sullivan, D. Garvey, 1994, Journal of medicinal chemistry.

Involvement of the TTX-resistant sodium channel Nav 1.8 in inflammatory and neuropathic, but not post-operative, pain states

J. Sullivan, C. Shieh, S. Baker, 2006, Pain.

Characterization of the ATP-sensitive potassium channels (KATP) expressed in guinea pig bladder smooth muscle cells.

J. Sullivan, J. Brioni, C. Shieh, 1999, The Journal of pharmacology and experimental therapeutics.

In vitro and in vivo characterization of a novel naphthylamide ATP‐sensitive K+ channel opener, A‐151892

J. Sullivan, C. Shieh, M. Gopalakrishnan, 2004, British journal of pharmacology.

(−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization

J. Sullivan, M. Williams, J. Brioni, 2002, Journal of Pharmacology and Experimental Therapeutics.

The discovery of a new class of large-conductance Ca2+-activated K+ channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles.

J. Sullivan, C. Shieh, M. Gopalakrishnan, 2003, Bioorganic & medicinal chemistry letters.

Effect of Cholinergic Enhancers on Basal Forebrain Function Governing Cortical Cerebral Blood Flow

S. Arneric, J. Sullivan, J. L. Raszkiewicz, 1995 .

Regulation of Human α4β2 Neuronal Nicotinic Acetylcholine Receptors by Cholinergic Channel Ligands and Second Messenger Pathways

J. Sullivan, M. Gopalakrishnan, E. Molinari, 1997 .

The oxidation of tryptamine by the two forms of monoamine oxidase in human tissues.

O. Hardiman, J. Sullivan, K. Tipton, 1986, Biochemical pharmacology.

Enhancement of apomorphine‐induced penile erection in the rat by a selective α1D‐adrenoceptor antagonist

J. Sullivan, J. Brioni, K. Andersson, 2002, British journal of pharmacology.

NPC 15437 interacts with the C1 domain of protein kinase C An analysis using mutant PKC constructs

J. Sullivan, B. Shearer, C. Tiffany, 1991, FEBS letters.

Effects of ATP‐sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction

J. Sullivan, J. Brioni, M. Gopalakrishnan, 2003, Neurourology and urodynamics.

Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H 3 receptor antagonist

K. Browman, J. Sullivan, J. Brioni, 2012 .

Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge.

J. Sullivan, R. Burch, L. Noronha-Blob, 1993, Journal of immunology.

Preclinical Profiling and Safety Studies of ABT‐769: A Compound with Potential for Broad‐spectrum Antiepileptic Activity

J. Waring, J. Sullivan, S. Chemburkar, 2005, Epilepsia.

Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain.

J. Sullivan, M. Decker, T. Ghayur, 2006, Behavioural brain research.

Regulation of human alpha4beta2 neuronal nicotinic acetylcholine receptors by cholinergic channel ligands and second messenger pathways.

J. Sullivan, M. Gopalakrishnan, E. Molinari, 1997, Molecular pharmacology.

Cellular distribution of the mRNA for the α7 subunit of the nicotinic acetylcholine receptor in the human cerebral cortex

T. Giordano, H. Schröder, S. Arneric, 1995 .

ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.

D. Donnelly-roberts, G. Gintant, J. Sullivan, 2006, CNS drug reviews.

Selective Localization and Selective Inhibition of Monoamine Oxidase in Human Brain

J. Sullivan, K. Tipton, C. Fowler, 1989 .

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, Min Zhang, K. Browman, 2012, Journal of Pharmacology and Experimental Therapeutics.

A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel Transient Receptor Potential Type V1 Receptor Antagonist, Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats

A. Gomtsyan, J. Sullivan, Chih-Hung Lee, 2005, Journal of Pharmacology and Experimental Therapeutics.

A-425619 [1-Isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a Novel and Selective Transient Receptor Potential Type V1 Receptor Antagonist, Blocks Channel Activation by Vanilloids, Heat, and Acid

A. Gomtsyan, J. Sullivan, Chih-Hung Lee, 2005, Journal of Pharmacology and Experimental Therapeutics.

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat

T. Brennan, J. Sullivan, M. Williams, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of 3-methyl-N-(1-oxy-3',4',5',6'-tetrahydro-2'H-[2,4'-bipyridine]-1'-ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction.

D. Donnelly-roberts, Jill M. Wetter, G. Gintant, 2006, Journal of medicinal chemistry.

Potassium channels: molecular defects, diseases, and therapeutic opportunities.

J. Sullivan, C. Shieh, M. Gopalakrishnan, 2000, Pharmacological reviews.

A sensitive technique for the detection of the α7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain

S. Arneric, J. Sullivan, J. Turek, 1995, Journal of Neuroscience Methods.

Human α4β2 Neuronal Nicotinic Acetylcholine Receptor in HEK 293 Cells: A Patch-Clamp Study

D. Bertrand, S. Arneric, J. Sullivan, 1996, The Journal of Neuroscience.

TRPV1 Receptors in the CNS Play a Key Role in Broad-Spectrum Analgesia of TRPV1 Antagonists

A. Gomtsyan, J. Sullivan, M. Decker, 2006, The Journal of Neuroscience.

a Novel Transient Receptor Potential Type V 1 Receptor Antagonist , Relieves Pathophysiological Pain Associated with Inflammation and Tissue Injury in Rats

A. Gomtsyan, J. Sullivan, Chih-Hung Lee, 2005 .

Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro.

J. Sullivan, R. Henry, M. Gopalakrishnan, 2004, Journal of medicinal chemistry.

Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs).

J. Sullivan, M. Gopalakrishnan, Henry Q. Zhang, 2002, Bioorganic & medicinal chemistry letters.

4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention.

J. Sullivan, G. Fox, A. Hancock, 2005, Journal of medicinal chemistry.

Pharmacological characterization of a 1,4‐dihydropyridine analogue, 9‐(3,4‐dichlorophenyl)‐3,3,6,6‐tetramethyl‐3,4,6,7,9,10‐hexahydro‐1,8(2H,5H)‐acridinedione (A‐184209) as a novel KATP channel inhibitor

J. Sullivan, M. Gopalakrishnan, S. Buckner, 2003, British journal of pharmacology.

Synthesis and Structure−Activity Relationships of a Novel Series of 2,3,5,6,7,9-Hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide KATP Channel Openers: Discovery of (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637), a Potent KATP Open

J. Sullivan, R. Henry, J. Brioni, 2004 .

Rotationally constrained 2,4-diamino-5,6-disubstituted pyrimidines: a new class of histamine H4 receptor antagonists with improved druglikeness and in vivo efficacy in pain and inflammation models.

Jill M. Wetter, M. McPherson, J. Sullivan, 2008, Journal of medicinal chemistry.

Emerging Pharmacologic Approaches for the Treatment of Lower Urinary Tract Disorders

J. Sullivan, J. Brioni, R. Moreland, 2004, Journal of Pharmacology and Experimental Therapeutics.

TREATMENT OF LOWER URINARY TRACT DISORDERS

J. Sullivan, J. Brioni, R. Moreland, 2004 .

Preclinical Pharmacology of ABT‐418: A Prototypical Cholinergic Channel Activator for the Potential Treatment of Alzheimer's Disease

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1995 .

Structural aspects of high affinity ligands for the α4β2 neuronal nicotinic receptor

J. Sullivan, M. Dart, M. Meyer, 2000 .

Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1998, Bioorganic & medicinal chemistry letters.

The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.

A. D. Rodrigues, J. Sullivan, D. Garvey, 1994, Drug metabolism and disposition: the biological fate of chemicals.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: In Vitro pharmacological properties of a novel, high affinity α4β2 nicotinic acetylcholine receptor ligand

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1996, Neuropharmacology.

The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain.

J. Sullivan, D. Anderson, M. Decker, 2000, European journal of pharmacology.

Structure-activity studies on a novel series of cholinergic channel activators based on a heteroaryl ether framework.

S. Arneric, J. Sullivan, D. Garvey, 1999, Bioorganic & medicinal chemistry letters.

ABT-089 [2-methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A potent and selective cholinergic channel modulator with neuroprotective properties.

D. Donnelly-roberts, D. Mckenna, S. Arneric, 1997, The Journal of pharmacology and experimental therapeutics.

ABT‐089 [3‐(2(S)‐pyrrolidinylmethoxy)‐2‐methyl‐pyridine]: An orally effective cholinergic channel modulator with potential once‐a‐day dosing and cardiovascular safety

S. Arneric, J. Sullivan, N. Lin, 1997 .

Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties.

A. D. Rodrigues, D. Donnelly-roberts, S. Arneric, 1997, Journal of medicinal chemistry.

2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands

S. Arneric, J. Sullivan, D. Garvey, 1996 .

Epibatidine: Pharmacological Properties of a Novel Nicotinic Acetylcholine Receptor Agonist and Analgesic Agent

J. Sullivan, A. Bannon, 1996 .

The pharmacology of (-)-nicotine and novel cholinergic channel modulators.

S. Arneric, J. Sullivan, J. Brioni, 1997, Advances in pharmacology.

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, K. Browman, Jill M. Wetter, 2005, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Thomas R. Miller, Gerard B. Fox, Jill M. Wetter, 2005, Journal of Pharmacology and Experimental Therapeutics.

Stable expression and pharmacological properties of the human alpha 7 nicotinic acetylcholine receptor.

D. Bertrand, D. Donnelly-roberts, S. Arneric, 1995, European journal of pharmacology.

J. Sullivan, R. Chess-Williams, M. Williams, 2002, Journal of Pharmacology and Experimental Therapeutics.

A-740003 [N-(1-{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat

D. Donnelly-roberts, J. Sullivan, P. Chandran, 2006, Journal of Pharmacology and Experimental Therapeutics.

Molecular characterization of human SUR2-containing K(ATP) channels.

Murali Gopalakrishnan, Paul E. Kroeger, R. Simmer, 2000, Gene.

Pharmacological characterization of a nicotinic autoreceptor in rat hippocampal synaptosomes

J. Sullivan, S. Wonnacott, P. Hutson, 1996, Neurochemical Research.

Activation of the recombinant human alpha 7 nicotinic acetylcholine receptor significantly raises intracellular free calcium.

J. Sullivan, M. Messi, O. Delbono, 1997, The Journal of pharmacology and experimental therapeutics.

Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.

M. Day, Rachel L Navarra, J. Sullivan, 2007, Biochemical pharmacology.

Section Review: Central & Peripheral Nervous Systems: Cholinergic channel modulators as a novel therapeutic strategy for Alzheimer's disease

S. Arneric, J. Sullivan, M. Holladay, 1996 .

Synthesis and structure-activity relationships of 2′-(R) and (S) pyrrolidine-modified analogs of the cholinergic channel activator, ABT-418

S. Arneric, J. Sullivan, N. Lin, 1995 .

Enzymological Aspects of the Actions of the Parkinsonism-Inducing Neurotoxin MPTP

J. Sullivan, K. Tipton, J. M. McCrodden, 1990 .

(R)-(5-tert-Butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) Blocks Polymodal Activation of Transient Receptor Potential Vanilloid 1 Receptors in Vitro and Heat-Evoked Firing of Spinal Dorsal Horn Neurons in Vivo

A. Gomtsyan, J. Sullivan, Chih-Hung Lee, 2008, Journal of Pharmacology and Experimental Therapeutics.

Stable expression, pharmacologic properties and regulation of the human neuronal nicotinic acetylcholine alpha 4 beta 2 receptor.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, The Journal of pharmacology and experimental therapeutics.

Interactions of the neurotoxin MPTP and its demethylated derivative (PTP) with monoamine oxidase-B

J. Sullivan, K. Tipton, 1992, Neurochemical Research.

Broad-Spectrum Efficacy across Cognitive Domains by α7 Nicotinic Acetylcholine Receptor Agonism Correlates with Activation of ERK1/2 and CREB Phosphorylation Pathways

J. Sullivan, C. Briggs, J. Buccafusco, 2007, The Journal of Neuroscience.

Generation and Therapeutic Efficacy of Highly Oligomer-Specific β-Amyloid Antibodies

H. Schoemaker, J. Sullivan, F. van Leuven, 2010, The Journal of Neuroscience.

Cholinergic channel activators: novel opportunities for the treatment of CNS disorders.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Proceedings of the Western Pharmacology Society.

K-ATP opener-mediated attenuation of spontaneous bladder contractions in ligature-intact, partial bladder outlet obstructed rats.

J. Sullivan, J. Brioni, J. J. Lynch, 2003, Life sciences.

(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: II. In vivo characterization.

J. Sullivan, J. L. Raszkiewicz, J. Brioni, 1994, The Journal of pharmacology and experimental therapeutics.

Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study.

M Gopalakrishnan, D Bertrand, D. Bertrand, 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

Functional Characterization of the Novel Neuronal Nicotinic Acetylcholine Receptor Ligand GTS-21 In Vitro and In Vivo

W. J. Jackson, D. Donnelly-roberts, S. Arneric, 1997, Pharmacology Biochemistry and Behavior.

Lycaconitine revisited: partial synthesis and neuronal nicotinic acetylcholine receptor affinities.

J. Sullivan, N. Lin, J. Jacyno, 1996, Journal of natural products.

In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1996, Brain Research.

Pharmacological Properties of ABT-239: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist

K. Browman, Jill M. Wetter, R. Porsolt, 2004 .

Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Association of Catsper1 or -2 with Cav3.3 Leads to Suppression of T-type Calcium Channel Activity*

J. Sullivan, J. Brioni, A. Saraf, 2006, Journal of Biological Chemistry.

Up-regulation of human alpha7 nicotinic receptors by chronic treatment with activator and antagonist ligands.

S. Arneric, J. Sullivan, M. Messi, 1998, European journal of pharmacology.

ABT-866, a novel α1A-adrenoceptor agonist with antagonist properties at the α1B- and α1D-adrenoceptor subtypes

J. Sullivan, M. Williams, J. Brioni, 2002 .

Central Mechanisms Regulating Penile Erection in Conscious Rats: The Dopaminergic Systems Related to the Proerectile Effect of Apomorphine

D. Donnelly-roberts, J. Sullivan, J. Brioni, 2004, Journal of Pharmacology and Experimental Therapeutics.

Substituted 2-(aminomethyl)piperidines: a novel class of selective protein kinase C inhibitors.

R. Patch, J. Sullivan, B. Shearer, 1991, Journal of Medicinal Chemistry.

Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.

K. Browman, J. Sullivan, M. E. Ballard, 2005, Inflammation Research.

A-186253, a specific antagonist of the α4β2 nAChRs: its properties and potential to study brain nicotinic acetylcholine receptors

D. Bertrand, J. Sullivan, E. Tribollet, 2004, Neuropharmacology.

A-315456: a selective α1D-adrenoceptor antagonist with minimal dopamine D2 and 5-HT1A receptor affinity

J. Sullivan, M. Nakane, J. Brioni, 2001 .

YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats.

J. Sullivan, J. Brioni, R. Moreland, 2003, European journal of pharmacology.

N-[3-(1H-imidazol-4-ylmethyl)phenyl]ethanesulfonamide (ABT-866, 1),(1) a novel alpha(1)-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine.

J. Sullivan, M. Nakane, M. Williams, 2002, Journal of medicinal chemistry.

Localization and Inhibition of Monoamine Oxidase

J. Sullivan, K. Tipton, L. Oreland, 1988 .

Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties.

D. Donnelly-roberts, S. Arneric, J. Sullivan, 1995, Alzheimer disease and associated disorders.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Journal of medicinal chemistry.

Dopamine D4 ligands and models of receptor activation: 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole and related heteroarylmethylarylpiperazines exhibit a substituent effect responsible for additional efficacy tuning.

D. Donnelly-roberts, J. Sullivan, M. Nakane, 2004, Journal of medicinal chemistry.

Effects of the cholinergic channel activator ABT‐418 on cortical EEG: Comparison with (−)‐nicotine

J. Sullivan, C. Briggs, C. Kang, 1996 .

Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides.

J. Sullivan, S. Meeker, D. Kyle, 1991, Agents and actions. Supplements.

Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides.

J. Sullivan, S. Meeker, D. Kyle, 1991, Journal of medicinal chemistry.

Gain of function mutation of the α7 nicotinic receptor: distinct pharmacology of the human α7V274T variant

D. Mckenna, S. Arneric, J. Sullivan, 1999 .

Molecular characterization of human SUR2-containing K(ATP) channels.

M Gopalakrishnan, R. Simmer, J. Sullivan, 2000, Gene.

Cell‐Based Assays Using the Fluorometric Imaging Plate Reader (FLIPR)

J. Sullivan, M. Gopalakrishnan, Kristi L. Whiteaker, 2000, Current protocols in pharmacology.

Determination of amines, amine metabolites and some amine metabolizing enzymes by high performance liquid chromatography.

J. Sullivan, K. Tipton, A. M. Wheatley, 1990, Biomedical chromatography : BMC.

Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variant.

D. Mckenna, S. Arneric, J. Sullivan, 1999, European journal of pharmacology.

The interactions of monoamine oxidase with some derivatives of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

J. Sullivan, K. Tipton, 1990, Journal of neural transmission. Supplementum.

NPC 15669 inhibits the reversed passive Arthus reaction in rats by blocking neutrophil recruitment.

J. Sullivan, J. Connor, R. Burch, 1992, The Journal of pharmacology and experimental therapeutics.

Metabolic aspects of the behavior of MPTP and some analogues.

J. Sullivan, K. Tipton, J. M. McCrodden, 1993, Advances in neurology.

Pharmacological and molecular analysis of ATP-sensitive K(+) channels in the pig and human detrusor.

J. Sullivan, J. Brioni, S. Buckner, 2000, European journal of pharmacology.

Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder.

J. Sullivan, M. Gopalakrishnan, M. Kort, 2004, Bioorganic & Medicinal Chemistry Letters.

Characterization of Neuronal Nicotinic Acetylcholine Receptors

J. Sullivan, David J. Anderson, 2001 .

Erysodine, a competitive antagonist at neuronal nicotinic acetylcholine receptors.

D. Donnelly-roberts, J. Sullivan, D. Anderson, 1995, European journal of pharmacology.

A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand.

D. Mckenna, S. Arneric, J. Sullivan, 1996, Neuropharmacology.

Functional modulation of human "ganglionic-like" neuronal nicotinic acetylcholine receptors (nAChRs) by L-type calcium channel antagonists.

S. Arneric, J. Sullivan, D. Donnelly‐Roberts, 1995, Biochemical and biophysical research communications.

Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury

Murali Gopalakrishnan, Prisca Honore, Char-Chang Shieh, 2004, Brain Research.

Histaminergic mechanisms in the CNS Selective H 3 receptor ( H 3 R ) blockade : broad efficacy in cognition and schizophrenia

K. Browman, J. Sullivan, M. E. Ballard, 2022 .

A. Gomtsyan, J. Sullivan, Chih-Hung Lee, 2008, Journal of Pharmacology and Experimental Therapeutics.

ABT-418: A Novel Cholinergic Channel Activator (ChCA) for the Potential Treatment of Alzheimer’s Disease

A. D. Rodrigues, S. Arneric, J. Sullivan, 1994 .

ABT — 418, a Novel Nicotinic Agonist

A. D. Rodrigues, W. J. Jackson, Y. Martin, 1994 .

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, K. Browman, J. Sullivan, 2012, Journal of Pharmacology and Experimental Therapeutics.

Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing alpha(1A)-adrenoceptor agonist.

J. Sullivan, M. Nakane, J. Kuk, 2004, Journal of medicinal chemistry.